1. Home
  2. WNEB vs EOLS Comparison

WNEB vs EOLS Comparison

Compare WNEB & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$13.77

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.63

Market Cap

284.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
EOLS
Founded
1853
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
284.3M
IPO Year
2001
2018

Fundamental Metrics

Financial Performance
Metric
WNEB
EOLS
Price
$13.77
$4.63
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$12.50
$15.50
AVG Volume (30 Days)
58.8K
794.8K
Earning Date
04-22-2026
05-04-2026
Dividend Yield
2.02%
N/A
EPS Growth
33.93
1.23
EPS
0.75
N/A
Revenue
$44,000.00
$297,176,000.00
Revenue This Year
N/A
$13.27
Revenue Next Year
$5.61
$17.62
P/E Ratio
$18.52
N/A
Revenue Growth
N/A
11.61
52 Week Low
$8.41
$3.86
52 Week High
$14.52
$12.28

Technical Indicators

Market Signals
Indicator
WNEB
EOLS
Relative Strength Index (RSI) 64.99 55.05
Support Level $12.07 $4.10
Resistance Level $13.95 $4.99
Average True Range (ATR) 0.27 0.21
MACD 0.11 0.06
Stochastic Oscillator 81.78 98.70

Price Performance

Historical Comparison
WNEB
EOLS

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: